SMS Lifesciences gets EIR from USFDA for API manufacturing facility in Telangana

24 Jun 2022 Evaluate

SMS Lifesciences India has received Establishment Inspection Report (EIR) from U.S. Food and Drug Administration (USFDA) for the inspection conducted in the month of April, 2022 at API manufacturing facility located at Kazipally, Jinnaram MandaI, Sangareddy district in Telangana. EIR from USFDA Indicates successful completion of the Inspection without any observations. 

SMS Lifesciences India is presently engaged in the business of manufacturing, buying, selling, offering consultancy, importing and exporting, acting as commission agents and generally dealing with of all types of Organic & Inorganic Chemicals, Pharmaceuticals, API and Intermediates.

SMS Lifesciences Share Price

1622.15 -42.75 (-2.57%)
22-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1747.25
Dr. Reddys Lab 1174.85
Cipla 1528.10
Lupin 2046.90
Zydus Lifesciences 852.50
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...